US-guided high-intensity focused ultrasound in pancreatic cancer treatment: a consensus initiative between Chinese and European HIFU centers

Refferences

• Carrato A, Falcone A, Ducreux M, et al. A systematic review of the burden of pancreatic cancer in Europe: real-World impact on survival, quality of life and costs. J Gastrointest Cancer. 2015;46(3):201–211. doi: 10.1007/s12029-015-9724-1.
   PubMedGoogle Scholar
• Murray CJ, Vos T, Lozano R, et al. Disability-adjusted life years (DALYs) for 291 diseases and injuries in 21 regions, 1990–2010: a systematic analysis for the global burden of disease study 2010. Lancet. 2012;380(9859):2197–2223. doi: 10.1016/S0140-6736(12)61689-4.
   PubMed Web of Science ®Google Scholar
• Grossberg AJ, Chu LC, Deig CR, et al. Multidisciplinary standards of care and recent progress in pancreatic ductal adenocarcinoma. CA Cancer J Clin. 2020;70(5):375–403. doi: 10.3322/caac.21626.
   PubMed Web of Science ®Google Scholar
• Vincent A, Herman J, Schulick R, et al. Pancreatic cancer. Lancet. 2011;378(9791):607–620. doi: 10.1016/S0140-6736(10)62307-0.
   PubMed Web of Science ®Google Scholar
• Ryan DP, Hong TS, Bardeesy N. Pancreatic adenocarcinoma. N Engl J Med. 2014;371(11):1039–1049. doi: 10.1056/NEJMra1404198.
   PubMed Web of Science ®Google Scholar
• Conroy T, Desseigne F, Ychou M, et al. FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N Engl J Med. 2011;364(19):1817–1825. doi: 10.1056/NEJMoa1011923.
   PubMed Web of Science ®Google Scholar
• Von Hoff DD, Ervin T, Arena FP, et al. Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine. N Engl J Med. 2013;369(18):1691–1703. doi: 10.1056/NEJMoa1304369.
   PubMed Web of Science ®Google Scholar
• Wang-Gillam A, Li CP, Bodoky G, et al. Nanoliposomal irinotecan with fluorouracil and folinic acid in metastatic pancreatic cancer after previous gemcitabine-based therapy (NAPOLI-1): a global, randomised, open-label, phase 3 trial. Lancet. 2016;387(10018):545–557. doi: 10.1016/S0140-6736(15)00986-1.
   PubMed Web of Science ®Google Scholar
• Wood LD, Canto MI, Jaffee EM, et al. Pancreatic cancer: pathogenesis, screening, diagnosis, and treatment. Gastroenterology. 2022;163(2):386–402.e1. doi: 10.1053/j.gastro.2022.03.056.
   PubMed Web of Science ®Google Scholar
• Lewis AR, Pihlak R, McNamara MG. The importance of quality-of-life management in patients with advanced pancreatic ductal adenocarcinoma. Curr Probl Cancer. 2018;42(1):26–39. doi: 10.1016/j.currproblcancer.2018.01.013.
   PubMed Web of Science ®Google Scholar
• Goldberg SN, Gazelle GS, Mueller PR. Thermal ablation therapy for focal malignancy: a unified approach to underlying principles, techniques, and diagnostic imaging guidance. AJR Am J Roentgenol. 2000;174(2):323–331. doi: 10.2214/ajr.174.2.1740323.
   PubMed Web of Science ®Google Scholar
• Keane MG, Bramis K, Pereira SP, et al. Systematic review of novel ablative methods in locally advanced pancreatic cancer. World J Gastroenterol. 2014;20(9):2267–2278. doi: 10.3748/wjg.v20.i9.2267.
   PubMed Web of Science ®Google Scholar
• Kovach SJ, Hendrickson RJ, Cappadona CR, et al. Cryoablation of unresectable pancreatic cancer. Surgery. 2002;131(4):463–464. doi: 10.1067/msy.2002.121231.
   PubMed Web of Science ®Google Scholar
• Kennedy JE. High-intensity focused ultrasound in the treatment of solid tumours. Nat Rev Cancer. 2005;5(4):321–327. doi: 10.1038/nrc1591.
   PubMed Web of Science ®Google Scholar
• Kennedy JE, Ter Haar GR, Cranston D. High intensity focused ultrasound: surgery of the future? Br J Radiol. 2003;76(909):590–599. doi: 10.1259/bjr/17150274.
   PubMed Web of Science ®Google Scholar
• Marinova M, Wilhelm-Buchstab T, Strunk H. Advanced pancreatic cancer: high-intensity focused ultrasound (HIFU) and other local ablative therapies. Rofo. 2019;191(3):216–227. doi: 10.1055/a-0820-5564.
   PubMedGoogle Scholar
• Jenne JW, Preusser T, Günther M. High-intensity focused ultrasound: principles, therapy guidance, simulations and applications. Z Med Phys. 2012;22(4):311–322. doi: 10.1016/j.zemedi.2012.07.001.
   PubMed Web of Science ®Google Scholar
• Li PZ, Zhu SH, He W, et al. High-intensity focused ultrasound treatment for patients with unresectable pancreatic cancer. Hepatobiliary Pancreat Dis Int. 2012;11(6):655–660. doi: 10.1016/s1499-3872(12)60241-0.
   PubMed Web of Science ®Google Scholar
• Marinova M, Huxold HC, Henseler J, et al. Clinical effectiveness and potential survival benefit of US-guided high-intensity focused ultrasound in patients with advanced pancreatic cancer. Ultraschall Med. 2018;40(5):625–637.
   PubMed Web of Science ®Google Scholar
• Marinova M, Strunk HM, Rauch M, et al. High-intensity focused ultrasound (HIFU) for tumor pain relief in inoperable pancreatic cancer: evaluation with the pain sensation scale (SES). Schmerz. 2017;31(1):31–39.
   PubMed Web of Science ®Google Scholar
• Orsi F, Zhang L, Arnone P, et al. High-intensity focused ultrasound ablation: effective and safe therapy for solid tumors in difficult locations. AJR Am J Roentgenol. 2010;195(3):W245–52. doi: 10.2214/AJR.09.3321.
   PubMed Web of Science ®Google Scholar
• Strunk HM, Henseler J, Rauch M, et al. Clinical use of high-intensity focused ultrasound (HIFU) for tumor and pain reduction in advanced pancreatic cancer. Rofo. 2016;188(7):662–670. doi: 10.1055/s-0042-105517.
   PubMedGoogle Scholar
• Wang K, Chen Z, Meng Z, et al. Analgesic effect of high intensity focused ultrasound therapy for unresectable pancreatic cancer. Int J Hyperthermia. 2011;27(2):101–107. doi: 10.3109/02656736.2010.525588.
   PubMed Web of Science ®Google Scholar
• Marinova M, Feradova H, Gonzalez-Carmona MA, et al. Improving quality of life in pancreatic cancer patients following high-intensity focused ultrasound (HIFU) in two european centers. Eur Radiol. 2021;31(8):5818–5829. doi: 10.1007/s00330-020-07682-z.
   PubMed Web of Science ®Google Scholar
• Vidal-Jove J, Perich E, del Castillo MA. Ultrasound guided high intensity focused ultrasound for malignant tumors: the Spanish experience of survival advantage in stage III and IV pancreatic cancer. Ultrason Sonochem. 2015;27:703–706. doi: 10.1016/j.ultsonch.2015.05.026.
   PubMed Web of Science ®Google Scholar
• Sofuni A, Asai Y, Mukai S, et al. High-intensity focused ultrasound therapy for pancreatic cancer. J Med Ultrason. 2022. doi: 10.1007/s10396-022-01208-4.
   Web of Science ®Google Scholar
• Hynynen K, Lulu BA. Hyperthermia in cancer treatment. Invest Radiol. 1990;25(7):824–834. doi: 10.1097/00004424-199007000-00014.
   PubMed Web of Science ®Google Scholar
• Wang G, Zhou D. Preoperative ultrasound ablation for borderline resectable pancreatic cancer: a report of 30 cases. Ultrason Sonochem. 2015;27:694–702. doi: 10.1016/j.ultsonch.2015.05.029.
   PubMed Web of Science ®Google Scholar
• Stanislavova N, Karamanliev M, Ivanov T, et al. Is high-intensity focused ultrasound (HIFU) an option for neoadjuvant therapy for borderline resectable pancreatic cancer patients? – A systematic review. Int J Hyperthermia. 2021;38(2):75–80. doi: 10.1080/02656736.2021.1909150.
   PubMed Web of Science ®Google Scholar
• Strunk HM, Lützow C, Henseler J, et al. Mesenteric vessel patency following HIFU therapy in patients with locally invasive pancreatic cancer. Ultraschall Med. 2018;39(6):650–658. doi: 10.1055/s-0043-125391.
   PubMed Web of Science ®Google Scholar
• Yu T, Luo J. Adverse events of extracorporeal ultrasound-guided high intensity focused ultrasound therapy. PLOS One. 2011;6(12):e26110. doi: 10.1371/journal.pone.0026110.
   PubMed Web of Science ®Google Scholar